Helicobacter pylori and peptic ulcer disease therapies: a survey of gastroenterologists in Israel.
BACKGROUND
Eradication of Helicobacter pylori has become a therapeutic option in the treatment of patients with peptic ulcer disease. The aim of this study was to evaluate the current management strategies of Israeli gastroenterologists in the diagnosis and treatment of H. pylori-related peptic ulcer disease, 14 years after the discovery of H. pylori.


METHODS
A questionnaire was mailed to all specialists in gastroenterology, members of the Israel Gastroenterological Association (IGA). Replies were received from 60% of Israel Board-certified gastroenterology specialists.


RESULTS
Over 89% of the gastroenterologists (89.1%) noted that they recommend anti-H. pylori treatment. 94.5% said that they treat duodenal ulcer in the first presentation with anti-H. pylori medication and 75% said that they do so in cases of recurrent duodenal ulcer. According to the replies received, there is a strong consensus towards triple treatment as the favored anti-H. pylori treatment; no one noted the use of dual treatment. Seven-day triple treatment was prescribed by 83.6% of the gastroenterologists who responded. Of these, the great majority, 89.1%, stated that they use proton pump inhibitors (PPI) in combination with any two of the following antibiotics: metronidazole (47.3%), tinidazole (29.1%), clarithromycin (61.8%), and amoxicillin (40%).


CONCLUSIONS
At the time of the survey, most Israel Board-certified gastroenterology specialists prescribed triple anti-H. pylori treatment of one-week's duration.
Fireman
Z
Z
Gastroenterology Department, Hillel Yaffe Medical Center, Hadera, Israel. fireman@post.tau.ac.il
Segal
A
A
Moshkowitz
M
M
Kopelman
Y
Y
Sternberg
A
A
D000658:Amoxicillin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use; D019538:Health Care Surveys; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007557:Israel; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use; D010406:Penicillins / Q000494:pharmacology / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000382:microbiology* / Q000628:therapy*; D054328:Proton Pump Inhibitors; D014011:Tinidazole / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D010406:Penicillins; D054328:Proton Pump Inhibitors; D014011:Tinidazole; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin